BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

9668

524735

HIKAL

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

HIKAL LIMITED performance

Today’s low

Today’s high

₹ 385.50 ₹ 403.25
₹ 387.75

52 week low

52 week high

₹ 267.25 ₹ 464.75
₹ 387.75

Open Price

₹ 394.35

Prev. Close

₹ 400.35

Volume (Shares)

225893.00

Total traded value

₹ 875.90

Upper Circuit

₹ 480.40

Lower Circuit

₹ 320.30

info

HIKAL LIMITED Share Price Update

As of the latest trading session, HIKAL LIMITED share price is currently at ₹ 387.75, which is down by ₹ -12.60 from its previous closing. Today, the stock has fluctuated between ₹ 385.50 and ₹ 403.25. Over the past year, HIKAL LIMITED has achieved a return of 27.71 %. In the last month alone, the return has been -3.35 %. Read More...

HIKAL LIMITED fundamentals


  • Market cap (Cr)

    4,780.98

  • P/E Ratio (TTM)

    64.21

  • Beta

    1.11

  • Book Value / share

    97.58

  • Return on equity

    5.99%

  • EPS (TTM)

    6.04

  • Dividend yield

    0.31%

  • Net profit/quarter (Cr)

    17.30

info icon alternate text
  • Market cap (Cr)

    4,776.05

  • P/E Ratio (TTM)

    64.21

  • Beta

    1.03

  • Book Value / share

    97.58

  • Return on equity

    5.99%

  • EPS (TTM)

    6.04

  • Dividend yield

    0.31%

  • Net profit/quarter (Cr)

    17.30

info icon alternate text

HIKAL LIMITED Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 438.90
Operating Expense 427.40
Net Profit 17.30
Net Profit Margin (%) 3.94
Earnings Per Share (EPS) 1.40
EBITDA 75.80
Effective Tax Rate (%) 27.61
Particulars SEP 2024 (Values in Cr)
Revenue 450.80
Operating Expense 428.70
Net Profit 18.10
Net Profit Margin (%) 4.01
Earnings Per Share (EPS) 1.47
EBITDA 75.10
Effective Tax Rate (%) 26.42
Particulars JUN 2024 (Values in Cr)
Revenue 403.80
Operating Expense 400.30
Net Profit 5.20
Net Profit Margin (%) 1.28
Earnings Per Share (EPS) 0.42
EBITDA 58.60
Effective Tax Rate (%) 25.71
Particulars MAR 2024 (Values in Cr)
Revenue 512.80
Operating Expense 467.40
Net Profit 33.90
Net Profit Margin (%) 6.61
Earnings Per Share (EPS) 2.75
EBITDA 94.89
Effective Tax Rate (%) 28.32
Particulars DEC 2023 (Values in Cr)
Revenue 438.50
Operating Expense 425.90
Net Profit 16.20
Net Profit Margin (%) 3.69
Earnings Per Share (EPS) 1.32
EBITDA 64.90
Effective Tax Rate (%) 25.34
Particulars MAR 2024 (Values in Cr)
Revenue 1768.70
Operating Expense 1691.70
Net Profit 69.50
Net Profit Margin (%) 3.92
Earnings Per Share (EPS) 5.65
EBITDA 269.40
Effective Tax Rate (%) 27.14
Particulars MAR 2023 (Values in Cr)
Revenue 2004.70
Operating Expense 1923.08
Net Profit 78.38
Net Profit Margin (%) 3.90
Earnings Per Share (EPS) 6.36
EBITDA 262.47
Effective Tax Rate (%) 25.60
Particulars MAR 2022 (Values in Cr)
Revenue 1926.03
Operating Expense 1729.04
Net Profit 160.51
Net Profit Margin (%) 8.33
Earnings Per Share (EPS) 13.02
EBITDA 345.45
Effective Tax Rate (%) 26.56
Particulars MAR 2021 (Values in Cr)
Revenue 1707.06
Operating Expense 1518.99
Net Profit 133.15
Net Profit Margin (%) 7.79
Earnings Per Share (EPS) 10.80
EBITDA 327.87
Effective Tax Rate (%) 35.49
Particulars MAR 2020 (Values in Cr)
Revenue 1462.12
Operating Expense 1368.99
Net Profit 84.43
Net Profit Margin (%) 5.77
Earnings Per Share (EPS) 6.85
EBITDA 261.45
Effective Tax Rate (%) 33.29
Particulars MAR 2024 (Values in Cr)
Book Value / Share 96.32
ROE % 6.00
ROCE % 7.51
Total Debt to Total Equity 0.67
EBITDA Margin 15.10
Particulars MAR 2023 (Values in Cr)
Book Value / Share 91.93
ROE % 7.12
ROCE % 8.20
Total Debt to Total Equity 0.65
EBITDA Margin 12.97
Particulars MAR 2022 (Values in Cr)
Book Value / Share 86.62
ROE % 16.04
ROCE % 14.86
Total Debt to Total Equity 0.64
EBITDA Margin 17.78
Particulars MAR 2021 (Values in Cr)
Book Value / Share 75.70
ROE % 15.22
ROCE % 15.93
Total Debt to Total Equity 0.72
EBITDA Margin 19.06
Particulars MAR 2020 (Values in Cr)
Book Value / Share 66.22
ROE % 12.06
ROCE % 13.35
Total Debt to Total Equity 0.83
EBITDA Margin 18.38
Particulars MAR 2024 (Values in Cr)
Book Value / Share 96.32
ROE % 5.99
ROCE % 7.51
Total Debt to Total Equity 0.67
EBITDA Margin 15.10
Particulars MAR 2023 (Values in Cr)
Book Value / Share 91.93
ROE % 7.12
ROCE % 8.20
Total Debt to Total Equity 0.65
EBITDA Margin 12.97
Particulars MAR 2022 (Values in Cr)
Book Value / Share 86.62
ROE % 16.04
ROCE % 14.86
Total Debt to Total Equity 0.64
EBITDA Margin 17.78
Particulars MAR 2021 (Values in Cr)
Book Value / Share 75.70
ROE % 15.22
ROCE % 15.93
Total Debt to Total Equity 0.72
EBITDA Margin 19.06
Particulars MAR 2020 (Values in Cr)
Book Value / Share 66.22
ROE % 12.06
ROCE % 13.35
Total Debt to Total Equity 0.83
EBITDA Margin 18.38
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 20.88
Total Assets 2487.14
Total Liabilities 2487.14
Total Equity 1187.66
Share Outstanding 123300750
Price to Book Ratio 2.75
Return on Assets (%) 2.79
Return on Capital (%) 3.48
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 59.54
Total Assets 2385.48
Total Liabilities 2385.48
Total Equity 1133.47
Share Outstanding 123300750
Price to Book Ratio 3.07
Return on Assets (%) 3.28
Return on Capital (%) 4.17
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 49.09
Total Assets 2213.10
Total Liabilities 2213.10
Total Equity 1067.98
Share Outstanding 123300750
Price to Book Ratio 4.65
Return on Assets (%) 7.25
Return on Capital (%) 9.21
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 36.80
Total Assets 1913.22
Total Liabilities 1913.22
Total Equity 933.40
Share Outstanding 123300750
Price to Book Ratio 1.90
Return on Assets (%) 6.95
Return on Capital (%) 8.63
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 63.57
Total Assets 1767.98
Total Liabilities 1767.98
Total Equity 816.50
Share Outstanding 123300750
Price to Book Ratio 1.06
Return on Assets (%) 4.77
Return on Capital (%) 6.13
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 20.77
Total Assets 2487.06
Total Liabilities 2487.06
Total Equity 1187.58
Share Outstanding 123300750
Price to Book Ratio 2.75
Return on Assets (%) 2.79
Return on Capital (%) 3.47
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 59.53
Total Assets 2385.47
Total Liabilities 2385.47
Total Equity 1133.48
Share Outstanding 123300750
Price to Book Ratio 3.07
Return on Assets (%) 3.28
Return on Capital (%) 4.17
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 49.09
Total Assets 2213.11
Total Liabilities 2213.11
Total Equity 1068.00
Share Outstanding 123300750
Price to Book Ratio 4.65
Return on Assets (%) 7.25
Return on Capital (%) 9.21
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 36.80
Total Assets 1913.23
Total Liabilities 1913.23
Total Equity 933.41
Share Outstanding 123300750
Price to Book Ratio 1.90
Return on Assets (%) 6.95
Return on Capital (%) 8.63
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 63.57
Total Assets 1767.99
Total Liabilities 1767.99
Total Equity 816.51
Share Outstanding 123300750
Price to Book Ratio 1.06
Return on Assets (%) 4.77
Return on Capital (%) 6.13
Particulars MAR 2024 (Values in Cr)
Net Income 95.50
Cash from Operations 217.05
Cash from Investing -173.74
Cash from Financing -26.99
Net change in Cash -14.02
Free Cash Flow 421.24
Particulars MAR 2023 (Values in Cr)
Net Income 105.36
Cash from Operations 344.10
Cash from Investing -292.34
Cash from Financing -7.68
Net change in Cash 15.28
Free Cash Flow 646.72
Particulars MAR 2022 (Values in Cr)
Net Income 218.55
Cash from Operations 363.53
Cash from Investing -284.37
Cash from Financing -5.55
Net change in Cash 3.80
Free Cash Flow 636.84
Particulars MAR 2021 (Values in Cr)
Net Income 206.42
Cash from Operations 275.51
Cash from Investing -156.19
Cash from Financing -96.86
Net change in Cash -24.04
Free Cash Flow 433.11
Particulars MAR 2020 (Values in Cr)
Net Income 141.98
Cash from Operations 324.63
Cash from Investing -163.79
Cash from Financing -100.86
Net change in Cash 20.26
Free Cash Flow 482.66
Particulars MAR 2024 (Values in Cr)
Net Income 95.41
Cash from Operations 216.95
Cash from Investing -173.74
Cash from Financing -26.99
Net change in Cash -14.11
Free Cash Flow 421.15
Particulars MAR 2023 (Values in Cr)
Net Income 105.35
Cash from Operations 344.09
Cash from Investing -292.34
Cash from Financing -7.68
Net change in Cash 15.27
Free Cash Flow 646.71
Particulars MAR 2022 (Values in Cr)
Net Income 218.56
Cash from Operations 363.53
Cash from Investing -284.37
Cash from Financing -5.55
Net change in Cash 3.80
Free Cash Flow 636.84
Particulars MAR 2021 (Values in Cr)
Net Income 206.42
Cash from Operations 275.51
Cash from Investing -156.19
Cash from Financing -96.86
Net change in Cash -24.04
Free Cash Flow 433.11
Particulars MAR 2020 (Values in Cr)
Net Income 141.98
Cash from Operations 324.63
Cash from Investing -163.79
Cash from Financing -100.86
Net change in Cash 20.26
Free Cash Flow 482.66
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

HIKAL LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
387.75 -3.14 redarrow
red-green-graph indicator
11 Bearish
5 Bullish
  • 5 Days 399.00
  • 26 Days 402.70
  • 10 Days 404.20
  • 50 Days 394.40
  • 12 Days 405.00
  • 100 Days 384.40
  • 20 Days 404.60
  • 200 Days 369.10
399.70 PIVOT

First Support

394.90

First Resistance

405.15

Second Support

389.45

Second Resistance

409.95

Third Support

384.65

Third Resistance

415.40

RSI

44.20

ADX

13.72

MACD

2.32

Williams % R

-91.09

Commodity Channel Index (CCI)

-87.00

Date

2025-04-30

Week

143315.00

Same Day

97174.00

Month

199192.00

1 Year

1.11

3 Year

0.95

Over 1 Month

-3.35%

down

Over 1 Year

27.71%

down

Over 3 Months

11.51%

down

Over 3 Years

0.54%

down

Over 6 Months

5.85%

down

Over 5 Years

28.14%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

HIKAL LIMITED shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
21.65%
Promoter Holdings
68.85%
FII
5.69%
DII
3.79%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Kalyani Investment Company Limited 3.8667375E7 (31.36%) Shareholding of Promoter and Promoter Group
Shri Badrinath Investment Pvt Ltd 1.9914862E7 (16.15%) Shareholding of Promoter and Promoter Group
Shri Rameshwara Investment Pvt Ltd 9810000.0 (7.96%) Shareholding of Promoter and Promoter Group
Sugandha J Hiremath 9667500.0 (7.84%) Shareholding of Promoter and Promoter Group
Tata Mutual Fund - Tata Small Cap Fund 3300000.0 (2.68%) Public Shareholding
Bf Investment Limited 3273375.0 (2.65%) Shareholding of Promoter and Promoter Group
Theleme India Master Fund Limited 2087351.0 (1.69%) Public Shareholding
Government Pension Fund Global 2034000.0 (1.65%) Public Shareholding
Jai V Hiremath 1340625.0 (1.09%) Shareholding of Promoter and Promoter Group
Ekdant Investment Pvt Ltd 393802.0 (0.32%) Shareholding of Promoter and Promoter Group
Sameer Jai Hiremath 390975.0 (0.32%) Shareholding of Promoter and Promoter Group
Pallavi Anish Swadi 381000.0 (0.31%) Shareholding of Promoter and Promoter Group
Sameer Trust 187500.0 (0.15%) Shareholding of Promoter and Promoter Group
Pallavi Trust 187500.0 (0.15%) Shareholding of Promoter and Promoter Group
Ashok Vishwanath Hiremath 100000.0 (0.08%) Shareholding of Promoter and Promoter Group
Anish Trust 75000.0 (0.06%) Shareholding of Promoter and Promoter Group
Pooja Trust 75000.0 (0.06%) Shareholding of Promoter and Promoter Group
Anika Trust 75000.0 (0.06%) Shareholding of Promoter and Promoter Group
Nihal Trust 75000.0 (0.06%) Shareholding of Promoter and Promoter Group
Rhea Trust 75000.0 (0.06%) Shareholding of Promoter and Promoter Group
Sumer Trust 75000.0 (0.06%) Shareholding of Promoter and Promoter Group
Karad Engineering Consultancy Pvt Ltd 63750.0 (0.05%) Shareholding of Promoter and Promoter Group
Decent Electronics Pvt Ltd 49500.0 (0.04%) Shareholding of Promoter and Promoter Group
Pooja Hiremath 7500.0 (0.01%) Shareholding of Promoter and Promoter Group
Anish Dilip Swadi 7500.0 (0.01%) Shareholding of Promoter and Promoter Group
Babasaheb Kalyani Family Trust 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

HIKAL LIMITED corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
20 Feb 2024 0.6 Interim 20 Feb 2024 Equity shares
18 Sep 2023 0.6 Final 19 Sep 2023 Equity shares
14 Feb 2023 0.6 Interim 14 Feb 2023 Equity shares
14 Sep 2022 0.4 Final 15 Sep 2022 Equity shares
23 Feb 2022 1.2 Interim 24 Feb 2022 Equity shares
25 Aug 2021 1.0 Final 26 Aug 2021 Equity shares
15 Feb 2021 1.0 Interim 16 Feb 2021 Equity shares
07 Sep 2020 0.2 Final 09 Sep 2020 Equity shares
17 Feb 2020 1.0 Interim 18 Feb 2020 Equity shares
23 Jul 2019 0.6 Final 25 Jul 2019 Equity shares
13 Feb 2019 0.6 Interim 14 Feb 2019 Equity shares
31 Jul 2018 0.5 Final 02 Aug 2018 Equity shares
21 Feb 2018 0.7 Interim 22 Feb 2018 Equity shares
02 Aug 2017 0.6 Final 04 Aug 2017 Equity shares
13 Feb 2017 0.6 Interim 14 Feb 2017 Equity shares
02 Aug 2016 0.5 Final 04 Aug 2016 Equity shares
17 May 2016 0.5 Interim 18 May 2016 Equity shares
04 Aug 2015 0.5 Final 06 Aug 2015 Equity shares
18 May 2015 0.5 Interim 19 May 2015 Equity shares
14 Aug 2014 2.5 Final 20 Aug 2014 Equity shares
18 Feb 2014 2.0 Interim 20 Feb 2014 Equity shares
13 Aug 2013 2.5 Final 16 Aug 2013 Equity shares
14 Aug 2012 6.0 Final 17 Aug 2012 Equity shares
09 Aug 2011 3.0 Final 11 Aug 2011 Equity shares
24 May 2011 3.0 Interim 25 May 2011 Equity shares
09 Aug 2010 4.0 Final 11 Aug 2010 Equity shares
11 May 2010 4.0 Interim 12 May 2010 Equity shares
11 Aug 2008 4.0 Final 13 Aug 2008 Equity shares
31 Jan 2008 3.0 Interim 01 Feb 2008 Equity shares
13 Aug 2007 3.5 Final 16 Aug 2007 Equity shares
14 Feb 2007 3.0 Interim 15 Feb 2007 Equity shares
11 Aug 2006 0.0 Final 01 Jan 0001 Equity shares
03 Feb 2006 0.0 Interim 01 Jan 0001 Equity shares
16 Aug 2005 0.0 Final 18 Aug 2005 Equity shares
08 Feb 2005 0.0 Interim 09 Feb 2005 Equity shares
Ex-Date Ex-Bonus Ratio
25 Jun 2018 22 Jun 2018 1:2
01 Oct 2003 29 Sep 2003 1:2
14 Sep 2000 21 Aug 2000 1:1
Ex-Date Old FV NEW FV Record Date
27 Feb 2015 10.0 2.0 02 Mar 2015
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
20 Feb 2024 0.6 Interim 20 Feb 2024 Equity shares
18 Sep 2023 0.6 Final 19 Sep 2023 Equity shares
14 Feb 2023 0.6 Interim 14 Feb 2023 Equity shares
14 Sep 2022 0.4 Final 15 Sep 2022 Equity shares
23 Feb 2022 1.2 Interim 24 Feb 2022 Equity shares
25 Aug 2021 1.0 Final 26 Aug 2021 Equity shares
15 Feb 2021 1.0 Interim 16 Feb 2021 Equity shares
07 Sep 2020 0.2 Final 09 Sep 2020 Equity shares
17 Feb 2020 1.0 Interim 18 Feb 2020 Equity shares
23 Jul 2019 0.6 Final 25 Jul 2019 Equity shares
13 Feb 2019 0.6 Interim 14 Feb 2019 Equity shares
31 Jul 2018 0.5 Final 02 Aug 2018 Equity shares
21 Feb 2018 0.7 Interim 22 Feb 2018 Equity shares
02 Aug 2017 0.6 Final 04 Aug 2017 Equity shares
13 Feb 2017 0.6 Interim 14 Feb 2017 Equity shares
02 Aug 2016 0.5 Final 04 Aug 2016 Equity shares
17 May 2016 0.5 Interim 18 May 2016 Equity shares
04 Aug 2015 0.5 Final 06 Aug 2015 Equity shares
18 May 2015 0.5 Interim 19 May 2015 Equity shares
14 Aug 2014 2.5 Final 20 Aug 2014 Equity shares
18 Feb 2014 2.0 Interim 20 Feb 2014 Equity shares
13 Aug 2013 2.5 Final 16 Aug 2013 Equity shares
14 Aug 2012 6.0 Final 17 Aug 2012 Equity shares
09 Aug 2011 3.0 Final 11 Aug 2011 Equity shares
24 May 2011 3.0 Interim 25 May 2011 Equity shares
09 Aug 2010 4.0 Final 11 Aug 2010 Equity shares
11 May 2010 4.0 Interim 12 May 2010 Equity shares
11 Aug 2008 4.0 Final 13 Aug 2008 Equity shares
31 Jan 2008 3.0 Interim 01 Feb 2008 Equity shares
13 Aug 2007 3.5 Final 16 Aug 2007 Equity shares
14 Feb 2007 3.0 Interim 15 Feb 2007 Equity shares
11 Aug 2006 0.0 Final 01 Jan 0001 Equity shares
03 Feb 2006 0.0 Interim 01 Jan 0001 Equity shares
16 Aug 2005 0.0 Final 18 Aug 2005 Equity shares
08 Feb 2005 0.0 Interim 09 Feb 2005 Equity shares
Ex-Date Ex-Bonus Ratio
25 Jun 2018 22 Jun 2018 1:2
01 Oct 2003 29 Sep 2003 1:2
14 Sep 2000 21 Aug 2000 1:1
Ex-Date Old FV NEW FV Record Date
27 Feb 2015 10.0 2.0 02 Mar 2015

HIKAL LIMITED Share Price

Hikal Limited, incorporated on July 08th, 1988, has emerged as one of the preferred partners for global companies in segments such as pharmaceuticals, crop protection, animal health, biocides, and specialty chemicals. The Company is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. Presently, it is operating in the crop protection and pharmaceuticals space.

The Company has 5 manufacturing facilities across three states in India. It supply products to customers across the globe in the US, Japan, Europe, Canada, South East Asia, LATAM, India and RoW. Apart from this, it specialize in manufacturing APIs and intermediates in pharmaceutical division. Within pharmaceutical division, it offer human health and animal health products.

Hikal commenced its first project in 1991 at its first greenfield site at M.I.D.C., Mahad with the manufacture of intermediates for agrochemical industry. It also bagged first big contract with Hoechst.

During 1996, Company came with public issue to part finance the expansion project of Thiabendazol. It achieved another milestone when Merck & Co., USA chose Hikal as a partner to outsource Thiabendazole (TBZ, a fungicide). Since the capacity at Mahad was inadequate, Hikal built second greenfield site, a state-of-the-art manufacturing facility at Taloja in 1997. The Company has been accorded Export House status by the Government of India. It set up a new manufacturing facility near Mumbai in collaboration with Merck & Co Inc, USA, for the manufacture of a post-harvest fungicide. It received the prestigious '5 star Safety Award' from British Safety Council' UK for high standards maintained at the Taloja Site.

During 1999-2000, the company has acquired an Agrochemical manufacturing site at Panoli, Gujarat from Novartis India Limited. The Company's status as an Export House has been elevated to that of a Trading House. In 2001, it entered the pharmaceuticals business, when it acquired the R&D Unit and Bulk Drug Manufacturing Facility of Wintac Ltd at Bangalore in Karnataka. In 2004, it built a brand new API plant post-acquisition and received USFDA certification. The Bangalore API Plant approved by USFDA and Australian TGA. During 2004-05, A 100% EOU plant for pharamaceutical intermediates is being set up. This unit is expected to be operational in the first half of the coming year.

During 2004-05, the company is establishing a state-of-the-art R&D facility in Pune and this research facility is expected to be operational in early 2006.

In Aug. 2004, the company has entered into an agreement with Bayer CropScience AG to manufacture and supply Agro biochemical intermediates and has set up a plant to manufacture this products in Mahad Plant. In 2005, the company made an agreement with Crompton Corporation, USA to manufacture and market a New Generation Crop protection product. In Nov. 2005, the company entered into a JV agreement with a subsidiary company of Sinochem Corporation, China.

During 2005-2006, the company made a strategic investment in Jiangsu Chemstar Industries Co (a subsidiary company of Sinochem Corporation China 'A Fortune 500 company). The company acquired 10% stake in the year. The companies production capacity of Crop protection products and Pharmaceutical products stood at 4436 MTn and 180 MT respectively.

The Company commenced export of Gabapentine to the US and Canada markets during FY 2006-07. It acquired Marsing & Co. A/S, Denmark and commenced marketing and distribution of APIs in various countries.

The Company increased investment to 16% in Jiangsu Chemstar Industries Co. Ltd., (a subsidiary company of Sinochem Corporation, China 'A FORTUNE 500' company) in FY'2007. During the year, it started supply of new Crop Protection product to one of the leading multinational companies. In Pharma plant, its existing Intermediate products registered increase in volumes and two new Pharma products were manufactured at Panoli site. R&D unit labs got upgraded and two new labs were added during the year 2007-08.

In 2008, the Company established Acoris Research Ltd., a contract research facility at the International Biotech Park, Pune, which is fully operational. In 2009, it expanded manufacturing capabilities. Construction of the new multi-purpose active ingredients plant for crop protection at the Taloja site was completed. It commissioned several new multipurpose API plants at the US FDA approved site in Bangalore. It commissioned a new multipurpose pharma intermediates plant at Panoli. Long-term contracts with global life sciences companies had a substantial impact on business. It signed long-term contract for a patented molecule with a leading multinational company.

As per the Scheme of Arrangement effective from 1st April 2012, the Research and Development activity of Acoris demerged with Hika. Acoris formerly a subsidiary is now a division of Hikal and further strengthened its capabilities, both in terms of manpower as well as technical capabilities.

During the year 2013, it signed a manufacturing agreement with a specialty US based food ingredient company. It completed initial supplies for advanced intermediates to one of the largest U.S. biotech companies. It signed a contract with a leading Japanese company to develop different peptides using their proprietary technology. In December 2016, Company sold its stake in subsidiary, Hikal International B.V.

In 2017, it sold the R&D unit in Bangalore. The Company issued Bonus Shares on 26 June 2018 in the ratio of 1:2 i.e. one bonus equity share of Rs. 2/- each fully paid-up for every two existing equity shares of Rs. 2/- each fully paid-up held by the members.

In 2023, new product launches in the antidiabetic therapeutic area gained significant traction among global customers. The Company made significant progress on the multi-year Animal Health project with a leading global innovator on developing product portfolio.

Parent organization Kalyani
NSE symbol HIKAL
Founded 1988
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Hikal Ltd?

Answer Field

The share price of Hikal Ltd for NSE is ₹ 387.75 and for BSE is ₹ 387.35.

What is the Market Cap of Hikal Ltd?

Answer Field

The market cap of Hikal Ltd for NSE is ₹ 47,80.98 Cr. and for BSE is ₹ 47,76.05 Cr. as of now.

What is the 52 Week High and Low of Hikal Ltd?

Answer Field

The 52 Week High and Low of Hikal Ltd for NSE is ₹ 464.75 and ₹ 267.25 and for BSE is ₹ 464.50 and ₹ 268.05.

How to Buy Hikal Ltd share?

Answer Field

You can trade in Hikal Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Hikal Ltd?

Answer Field

The 1 year returns on the stock has been 27.71%.

What is the Current Share Price of Hikal Ltd?

Answer Field

Hikal Ltd share price is for NSE ₹ 387.75 & for BSE ₹ 387.35 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Hikal Ltd Share?

Answer Field

The market cap of Hikal Ltd for NSE ₹ 47,80.98 & for BSE ₹ 47,76.05 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Hikal Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Hikal Ltd share is 64.21.

What is the PB ratio of Hikal Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Hikal Ltd share is 97.58.

How to Buy Hikal Ltd Share?

Answer Field

You can trade in Hikal Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Hikal Ltd Share on Bajaj Broking App?

Answer Field

To buy Hikal Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Hikal Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|